Group 1 - The company reported a strong performance in Q4, with positive results from both end markets and product execution [2] - In the diagnostics segment, reproductive health and newborn screening performed particularly well, while immunodiagnostics showed strong results outside of China [2] - The company observed stabilization in the pharma biotech sector, which positively influenced its overall results [2] Group 2 - The company executed effectively across its profit and loss statement, positioning itself favorably for 2026 [3]